Janssen to Move forward with Clinical Development of LAVA Therapeutics’s Lead Gamma-Delta T-Cell Engager Bispecific Antibody

(24/7 MARKET NEWS) – LAVA Therapeutics N.V. (Nasdaq:LVTX) stated, after yesterday’s market close, that Janssen Biotech, Inc., a part of the Janssen Pharmaceutical Companies of Johnson & Johnson, has chosen a lead candidate aimed at an undisclosed tumor-associated antigen for further development towards clinical settings.

LAVA Therapeutics is trading at $2.37, up $0.47 (+24.73%), on 720.85K premarket shares traded.

Its 52-week range is $1.365 to $7.38. If its trading volume increases, it’s close to breaking the resistance between here and February’s $3.50-$4 range.

24/7 MARKET NEWS, INC Disclaimer

24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.

Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.